ATE442451T1 - Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung - Google Patents

Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung

Info

Publication number: ATE442451T1
Authority: AT; Austria
Prior art keywords: ala; leu; seq; thr; glu
Prior art date: 2005-02-25

Application number

AT06709536T

Other languages

English (en)

Inventor

Yu-Chun Lone

Anthony Pajot

Original Assignee

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-25

Filing date

2006-02-24

Publication date

2009-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442451(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-24 Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE442451T1 publication Critical patent/ATE442451T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
108020004707 nucleic acids Proteins 0.000 abstract 4
150000007523 nucleic acids Chemical class 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 4
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
108010093013 HLA-DR1 Antigen Proteins 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
230000036436 anti-hiv Effects 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
238000009007 Diagnostic Kit Methods 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
108010090804 Streptavidin Proteins 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
125000006850 spacer group Chemical group 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

AT06709536T 2005-02-25 2006-02-24 Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung ATE442451T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0550520A FR2882557A1 (fr)	2005-02-25	2005-02-25	Epitopes de vih et composition pharmaceutique les contenant
PCT/FR2006/050167 WO2006090090A2 (fr)	2005-02-25	2006-02-24	Epitopes de vih et composition pharmaceutique les contenant

Publications (1)

Publication Number	Publication Date
ATE442451T1 true ATE442451T1 (de)	2009-09-15

Family

ID=34954973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06709536T ATE442451T1 (de)	2005-02-25	2006-02-24	Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung

Country Status (9)

Country	Link
US (1)	US20110142911A1 (de)
EP (1)	EP1851321B1 (de)
JP (1)	JP2008531530A (de)
AT (1)	ATE442451T1 (de)
CA (1)	CA2598929A1 (de)
DE (1)	DE602006009077D1 (de)
ES (1)	ES2332532T3 (de)
FR (1)	FR2882557A1 (de)
WO (1)	WO2006090090A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2535034C2 (ru) *	2010-08-06	2014-12-10	Олег Ильич Эпштейн	Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
KR101476255B1 (ko) *	2014-02-07	2014-12-26	대한민국	HIV-l 유래 T 세포 항원결정기를 갖는 재조합 펩타이드 및 이를 포함하는 백신 조성물
TW201907937A (zh)	2017-05-08	2019-03-01	美商葛利史東腫瘤科技公司	阿爾法病毒新抗原載體
MX2021014525A (es)	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
WO2020248032A1 (pt) *	2019-06-10	2020-12-17	Ricardo Diaz	Método para a definição de uma vacina personalizada contra o hiv/aids
AU2020298552A1 (en) *	2019-07-02	2022-03-03	Seattle Project Corp.	HIV antigens and MHC complexes
EP4192496A4 (de)	2020-08-06	2025-01-01	Gritstone bio, Inc.	Multiepitop-impfstoffkassetten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR910002374B1 (ko) *	1985-04-29	1991-04-20	제네틱 시스템즈 코포레이션	Aids 관련질병의 검출을 위한 합성항원
US5034511A (en) *	1987-04-13	1991-07-23	Institut Pasteur	Variant of LAV viruses
GB8910145D0 (en) *	1989-05-03	1989-06-21	Connaught Lab	Synthetic peptides for an hiv-1 vaccine
ES2187947T5 (es) *	1997-03-10	2014-01-29	Roche Diagnostics Gmbh	Procedimiento para la detección simultánea de antígenos de HIV y anticuerpos de HIV
US6548527B2 (en) *	2000-03-27	2003-04-15	The General Hospital Corporation	Treatments for immune-mediated ear disorders
AU2003245729A1 (en) *	2002-06-27	2004-01-19	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7663017B2 (en) *	2003-07-30	2010-02-16	Institut Pasteur	Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications

2005
- 2005-02-25 FR FR0550520A patent/FR2882557A1/fr not_active Withdrawn
2006
- 2006-02-24 AT AT06709536T patent/ATE442451T1/de not_active IP Right Cessation
- 2006-02-24 ES ES06709536T patent/ES2332532T3/es not_active Expired - Lifetime
- 2006-02-24 EP EP06709536A patent/EP1851321B1/de not_active Revoked
- 2006-02-24 JP JP2007556639A patent/JP2008531530A/ja active Pending
- 2006-02-24 DE DE602006009077T patent/DE602006009077D1/de not_active Expired - Lifetime
- 2006-02-24 WO PCT/FR2006/050167 patent/WO2006090090A2/fr not_active Ceased
- 2006-02-24 CA CA002598929A patent/CA2598929A1/fr not_active Abandoned
2007
- 2007-08-20 US US11/894,172 patent/US20110142911A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2006090090A3 (fr)	2006-12-07
US20110142911A1 (en)	2011-06-16
EP1851321B1 (de)	2009-09-09
JP2008531530A (ja)	2008-08-14
DE602006009077D1 (de)	2009-10-22
EP1851321A2 (de)	2007-11-07
ES2332532T3 (es)	2010-02-08
WO2006090090A2 (fr)	2006-08-31
FR2882557A1 (fr)	2006-09-01
CA2598929A1 (fr)	2006-08-31

Similar Documents

Publication	Publication Date	Title
Gong et al.	2022	Peptide-based vaccines for tuberculosis
Tan et al.	2021	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Pardieck et al.	2022	A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
Kramer et al.	2022	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
Earnhart et al.	2007	An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences
US20240216507A1 (en)	2024-07-04	Sars-cov-2-specific t cells and methods of treatment using them
Kelly et al.	1995	T-cell, adhesion, and B-cell epitopes of the cell surface Streptococcus mutans protein antigen I/II
SA519410007B1 (ar)	2023-02-16	مركبات ببتيد وطرق لمعالجة السكر
DE602006009077D1 (de)	2009-10-22	Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung
CA2416761A1 (fr)	2002-01-31	Procede de criblage de peptides utilisables en immunotherapie
Baier et al.	1995	Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro
JP2007526318A (ja)	2007-09-13	Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫原性組成物
Romano et al.	2004	Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of Mycobacterium tuberculosis
CN100415771C (zh)	2008-09-03	激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
Agrawal et al.	2003	Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity
AR004567A1 (es)	1998-12-16	Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
WO2001016174A2 (en)	2001-03-08	Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
CN101370517B (zh)	2012-12-05	来源于c型肝炎病毒的肽
CN1954217A (zh)	2007-04-25	衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
ES2573105T3 (es)	2016-06-06	Secuencias de péptidos y composiciones
WO2007005627A8 (en)	2008-10-16	Tuberculosis antigen detection assays and vaccines
Gadzinski et al.	2012	Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens
Norimine et al.	2006	Quantitation of Anaplasma marginale major surface protein (MSP) 1a and MSP2 epitope-specific CD4+ T lymphocytes using bovine DRB3* 1101 and DRB3* 1201 tetramers
Fonseca et al.	2000	Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis
Cadogan et al.	2008	HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties